Navigation Links
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American Society of Clinical Oncology annual meeting this May 28th and 29th in Orlando, Florida. Both programs target unique pathways with the potential for broad application to a wide variety of cancer types.

TRC105 is a monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. CD105 is also expressed on cancer stem cells.

TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)).

"TRACON remains on schedule to deliver three Phase 2-ready assets in 2009 including two monoclonal antibodies," commented Charles P. Theuer MD PhD, President and CEO of TRACON Pharmaceuticals. "We are currently engaged in manufacturing and clinical development activities to support comprehensive Phase 2 programs."

The presentation details are as follows:

    TRC105
    Abstract Title: Phase 1 study of TRC105 (anti-CD105 (endoglin) antibody)
    therapy in patients with advanced refractory cancer
    Presenter: Lee Rosen, MD, Premiere Oncology - Los Angeles
    Date and Time: Friday, May 29, 2009, 2:00 PM - 6:00 PM
    Session Title: Developmental Therapeutics
    Session Type: Poster Discussion
    Abst
'/>"/>
SOURCE TRACON Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
2. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
3. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
4. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
5. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
6. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
7. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
8. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
9. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
10. Transcept Pharmaceuticals to Report First Quarter 2009 Results
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July, 29  2014 ISPE—the International Society ... John Bournas as President and CEO, ... to leave the Society last fall.  Mr. Bournas ... in the healthcare association industry as well as ... a clear vision for the expansion of its ...
(Date:7/29/2014)... , July 29, 2014 Numotion,s Board of Directors ... Swinford will be the company,s new Chief Executive Officer. ... 22-year career at GE where he worked primarily for GE ... revenue to over $5 billion. His most recent position was ... "I am thrilled to join Numotion," said ...
(Date:7/29/2014)... and NEW YORK , July 29, ... executive management team of Caremark Rx, Drew Crawford ... www.pbm365.com ).  PBM365 is the leading independent media source ... insight, analysis and opinion on the pharmacy benefit management ... insightful and timely coverage of, and context behind, industry ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Numotion Names Mike Swinford CEO 2Drew Crawford Announces Launch of PBM365 Media 2
... K-V Pharmaceutical Company ( KVa; KVb) (the "Company") ... HOLX ) that site initiation and patient enrollment has ... in the ongoing trial of Gestiva™ (hydroxyprogesterone caproate injection, 250 ... of preterm birth in women pregnant with a single baby ...
... The Wireless-Life Sciences Alliance (WLSA) , which convenes innovators, globally relevant ... in wireless technologies, today hailed its partner organizations for their collaboration and ... , , ... , , ...
Cached Medicine Technology:K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 2K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 3K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 4K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 5K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 6K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 7K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 8K-V Pharmaceutical Announces Update on Confirmatory Trial of Gestiva(TM) 9Wireless-Life Sciences Alliance (WLSA) Applauds Partner Organizations for Supporting Goal of Improving Healthcare Via Wireless Technologies 2Wireless-Life Sciences Alliance (WLSA) Applauds Partner Organizations for Supporting Goal of Improving Healthcare Via Wireless Technologies 3
(Date:7/29/2014)... July 29, 2014 Biocides are chemical ... control bacteria or fungi growth and to prevent degradation ... the material and its surface. It is used in ... preservation, food and beverage, paints and coatings. It is ... sanitizers, as well as in industrial applications to prevent ...
(Date:7/29/2014)... Crohn,s and Colitis Canada has invested $3.4 million ... disease and ulcerative colitis, debilitating chronic diseases that ... grants will support 9 promising research projects across ... environmental causes of the diseases, improve our understanding ... to improve patient care and quality of life. ...
(Date:7/29/2014)... materials capable of repelling bacteria have each won ... to find out why. , Their bacteria ... in hospital infections acquired through implanted medical devices ... across the globe. , Morgan Alexander, Professor of ... Paul Williams, Professor of Molecular Microbiology, in the ...
(Date:7/29/2014)... the increasing use of electronic medical records and ... for a computerized version of the preventive care ... a new study, researchers from the Indiana University ... that substantial work lies ahead to convert the ... computerized prompts for physicians, but the payoff has ...
(Date:7/29/2014)... -- The U.S. should significantly reform the federal ... to ensure that the public,s $15 billion annual ... needs, says a new report by the Institute ... through Medicare -- requires little accountability, allocates funds ... offers insufficient opportunities to train physicians in the ...
Breaking Medicine News(10 mins):Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:Prestigious Crohn's and Colitis Canada grants fund promising Canadian research 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 3Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 2Health News:$15 billion annual public funding system for doctor training needs overhaul, says IOM 3
... Complex Rehab Market , , ... with 35 years of experience, has joined Alliance Seating ... complex rehab companies. O,Neill is an Assistive Technology Supplier ... and is responsible for sales and service of rehabilitation equipment ...
... 16 For the past 40 years, arc Thrift ... developmental,disabilities. This week, The Melvin and Elaine Wolf ... a Purpose" program. "As,one of the larger employers of ... partner with The Melvin and Elaine Wolf Foundation to ...
... a neurodegenerative disorder that causes the weakening of muscles, ... in 1 in 6,000 live births. While trans-splicing ... as a treatment for spinal muscular atrophy in cell-based ... the therapy to the human body. A University of ...
... The Journal of Nuclear Medicine SNM,s flagship publicationwill ... change to the publication allows the generous use of ... of research reports," said Heinrich R. Schelbert, M.D., editor ... . "Most important and critical, it strengthens the communication ...
... Mo. Evolving HIV viral strains and the adverse ... treatments propel scientists to continue exploring alternative HIV ... Missouri researcher has identified broad-spectrum aptamers. Aptamers are ... reproducing. In lab tests, aptamers known as RT5, ...
... autism are,struggling with a host of worries that impact ... their family will lack the life-long supports,needed to address ... released today by Easter Seals and made possible by ... Autism Study results reveal parents raising,children with autism are ...
Cached Medicine News:Health News:Veteran Rehab Specialist, Ted O'Neill, Joins Fast-Growing Alliance Seating & Mobility in Pennsylvania 2Health News:The Melvin and Elaine Wolf Foundation Donates $10,000 to arc Thrift Stores 2Health News:Journal of Nuclear Medicine premiers new, full-color design 2Health News:Researcher refining synthetic molecules to prevent HIV resistance 2Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 2Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 3Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 4Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 5Health News:Easter Seals' Study Sheds New Light on Parents' Life-Long Fears, Anxieties and Critical Supports Needed to Raise a Child With Autism 6
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: